The intranasal dexmedetomidine plus ketamine for procedural sedation in children, adaptive randomized controlled non-inferiority multicenter trial (Ketodex): a statistical analysis plan

Anna Heath, Juan David Rios, Eleanor Pullenayegum, Petros Pechlivanoglou, Martin Offringa, Maryna Yaskina, Rick Watts, Shana Rimmer, Terry P Klassen, Kamary Coriolano, Naveen Poonai, PERC-KIDSCAN Ketodex Study Group, Darcy Beer, Scott Sawyer, Maala Bhatt, April Kam, Quynh Doan, Vikram Sabhaney, Serena Hickes, Samina Ali, Karly Stillwell, Tannis Erickson, Chelsea Bowkett, Carolyn Shimmin, Brendon Foot, Chelsea Bowkett, Candace McGahern, Redjana Carciurmaruj, Jeannine Schellenberg, Anna Heath, Juan David Rios, Eleanor Pullenayegum, Petros Pechlivanoglou, Martin Offringa, Maryna Yaskina, Rick Watts, Shana Rimmer, Terry P Klassen, Kamary Coriolano, Naveen Poonai, PERC-KIDSCAN Ketodex Study Group, Darcy Beer, Scott Sawyer, Maala Bhatt, April Kam, Quynh Doan, Vikram Sabhaney, Serena Hickes, Samina Ali, Karly Stillwell, Tannis Erickson, Chelsea Bowkett, Carolyn Shimmin, Brendon Foot, Chelsea Bowkett, Candace McGahern, Redjana Carciurmaruj, Jeannine Schellenberg

Abstract

Background: Procedural sedation and analgesia (PSA) is frequently required to perform closed reductions for fractures and dislocations in children. Intravenous (IV) ketamine is the most commonly used sedative agent for closed reductions. However, as children find IV insertion a distressing and painful procedure, there is need to identify a feasible alternative route of administration. There is evidence that a combination of dexmedetomidine and ketamine (ketodex), administered intranasally (IN), could provide adequate sedation for closed reductions while avoiding the need for IV insertion. However, there is uncertainty about the optimal combination dose for the two agents and whether it can provide adequate sedation for closed reductions. The Intranasal Dexmedetomidine Plus Ketamine for Procedural Sedation (Ketodex) study is a Bayesian phase II/III, non-inferiority trial in children undergoing PSA for closed reductions that aims to address both these research questions. This article presents in detail the statistical analysis plan for the Ketodex trial and was submitted before the outcomes of the trial were available for analysis.

Methods/design: The Ketodex trial is a multicenter, four-armed, randomized, double-dummy controlled, Bayesian response adaptive dose finding, non-inferiority, phase II/III trial designed to determine (i) whether IN ketodex is non-inferior to IV ketamine for adequate sedation in children undergoing a closed reduction of a fracture or dislocation in a pediatric emergency department and (ii) the combination dose for IN ketodex that provides optimal sedation. Adequate sedation will be primarily measured using the Pediatric Sedation State Scale. As secondary outcomes, the Ketodex trial will compare the length of stay in the emergency department, time to wakening, and adverse events between study arms.

Discussion: The Ketodex trial will provide evidence on the optimal dose for, and effectiveness of, IN ketodex as an alternative to IV ketamine providing sedation for patients undergoing a closed reduction. The data from the Ketodex trial will be analyzed from a Bayesian perspective according to this statistical analysis plan. This will reduce the risk of producing data-driven results introducing bias in our reported outcomes.

Trial registration: ClinicalTrials.gov NCT04195256 . Registered on December 11, 2019.

Keywords: Bayesian adaptive design; Intranasal ketodex; Non-inferiority trial; Pediatric closed reduction; Procedural sedation and analgesia; Statistical analysis plan.

Conflict of interest statement

None reported.

Figures

Fig. 1
Fig. 1
Depiction of the randomization procedure for the Ketodex trial

References

    1. Chamberlain J, Patel K, Pollack M, Brayer A, Macias C, Okada P, Schunk J, and others Recalibration of pediatric risk of admission score using a multi-institutional samples. Ann Emerg Med. 2004;43(4):461–468.
    1. Rennie L, Court-Brown C, Mok J, Beattie T. The epidemiology of fractures in children. Injury. 2007;38(8):913–922.
    1. Cheng J, Shen W. Limb fracture pattern in different pediatric age groups: a study of 3,350 children. J Orthop Trauma. 1993;7(1):15–22.
    1. Jones K, Weiner D. The management of forearm fractures in children: a Plea for conservatism. J Pediatr Orthop. 1999;19(6):811.
    1. Schofield S, Schutz J, Babl F. Procedural sedation and analgesia for reduction of distal forearm fractures in the paediatric emergency department: a clinical survey. Emerg Med Aust. 2013;25(3):241–247.
    1. Cummings E, Reid G, Finley G, McGrath P, Ritchie J. Prevalence and source of pain in pediatric inpatients. Pain. 1996;68(1):25–31.
    1. Graudins A, Meek R, Egerton-Warburton D, Oakley E, Seith R. The PICHFORK (Pain in Children Fentanyl or Ketamine) trial: a randomized controlled trial comparing intranasal ketamine and fentanyl for the relief of moderate to severe pain in children with limb injuries. Ann Emerg Med. 2015;65(3):248–254.
    1. Poonai N, Spohn J, Vandermeer B, Ali S, Bhatt M, Hendrikx S, et al. Intranasal dexmedetomidine for anxiety-provoking procedures in children: a systematic review and meta-analysis. Pediatrics. 2020;145(1):e20191623.
    1. Heath A, Yaskina M, Pechlivanoglou P, Rios J, Offringa M, Klassen T, Poonai N, Pullenayegum E. A Bayesian response-adaptive dose finding and comparative effectiveness trial. Clinical Trials. 2020. 10.1177/1740774520965173, p. epub.
    1. Poonai N, Coriolano K, Klassen T, Heath A, Yaskina M, Beer D, Sawyer S, Bhatt M, Kam A, Doan Q, Sabhaney V, Offringa M, Pechlivanoglou P, Hickes S, Ali S. Study protocol for intranasal dexmedetomidine plus ketamine for procedural sedation in children: an adaptive randomized controlled non-inferiority multicenter trial (the Ketodex trial). BMJ Open. 2020;10:e041319.
    1. Gamble C, Krishan A, Stocken D, Lewis S, Juszczak E, Doré C, Williamson P, Altman D, Montgomery A, Lim P, Berlin J. Guidelines for the content of statistical analysis plans in clinical trials. Jama. 2017;318(23):2337–2343.
    1. Kelly L, Richer L, Ali S, Plint A, Poonai N, Freedman S, Knisley L, Shimmin C, Hickes S, W’t Jong G, Pechlivanoglou P. Innovative approaches to investigator-initiated, multicentre paediatric clinical trials in Canada. BMJ Open. 2019;9(6):e029024.
    1. Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381.
    1. WCHRI, “Women and Children's Health Research Institute, (WCHRI). Data Coordinating Centre.,” . Accessed August 7, 2018. 2018.
    1. Cravero J, Askins N, Sriswasdi P, Tsze D, Zurakowski D, Sinnott S. Validation of the Pediatric Sedation State Scale. Pediatrics. 2017;139(5):e20162897.
    1. Hicks C, von Baeyer C, Spafford P, van Korlaar I, Goodenough B. The Faces Pain Scale–Revised: toward a common metric in pediatric pain measurement. Pain. 2001;93(2):173–183.
    1. Cao J, Lee J, Alber S. Comparison of Bayesian sample size criteria: ACC, ALC, and WOC. J Stat Plann Inference. 2009;139:4111–4122.
    1. Berger J, Wolpert R. IMS. The likelihood principle. Hayward, California: Institute of Mathematic Statistics; 1988.
    1. R Core Team . R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
    1. Plummer M. Proceedings of the 3rd international workshop on distributed statistical computing, vol. 124, no. 125.10. 2003. JAGS: a program for analysis of Bayesian graphical models using Gibbs sampling; pp. 1–10.
    1. Bhat R, Santhosh M, Annigeri V, Rao R. Comparison of intranasal dexmedetomidine and dexmedetomidine-ketamine for premedication in pediatrics patients: a randomized double-blind study. Anesth Essays Res. 2016;10(2):349.
    1. Morita S, Thall P, Müller P. Determining the effective sample size of a parametric prior. Biometrics. 2008;64(2):595–602.
    1. Cai C, Yuan Y, Ji Y. A Bayesian dose finding design for oncology clinical trials of combinational biological agents. J R Stat Soc: Ser C: Appl Stat. 2014;63(1):159–173.
    1. Wang K, Ivanova A. Two-dimensional dose finding in discrete dose space. Biometrics. 2005;61(1):217–222.
    1. Gelman A, Jakulin A, Pittau M, Su Y. A weakly informative default prior distribution for logistic and other regression models. Ann Appl Stat. 2008;2(4):1360–1383.
    1. Kannikeswaran N, Lieh-Lai M, Malian M, Wang B, Farooqi A, Roback M. Optimal dosing of intravenous ketamine for procedural sedation in children in the ED—a randomized controlled trial. Am J Emerg Med. 2016;34(8):1347–1353.
    1. Gelman A, Shalizi C. Philosophy and the practice of Bayesian statistics. Br J Math Stat Psychol. 2013;66(1):8–38.
    1. Gelman A. Prior distributions for variance parameters in hierarchical models (comment on article by Browne and Draper) Bayesian Anal. 2006;1(3):515–534.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever